How is the Generalized Anxiety Disorder 7 (GAD‑7) questionnaire administered, scored, interpreted, and what treatment is recommended for each score category?

GAD-7 Administration, Scoring, Interpretation, and Treatment

Administration

The GAD-7 is a 7-item self-report questionnaire that asks patients how often they have been bothered by specific anxiety symptoms over the past 2 weeks. 1

• Each item is rated on a 4-point Likert scale: 0 = "not at all," 1 = "several days," 2 = "more than half the days," and 3 = "nearly every day" 1
• The seven items assess: feeling nervous/anxious/on edge; inability to stop or control worrying; worrying too much about different things; trouble relaxing; being so restless it's hard to sit still; becoming easily annoyed or irritable; and feeling afraid as if something awful might happen 1
• A final question asks about functional impairment: "How difficult have these problems made it for you to do your work, take care of things at home, or get along with other people?" 1, 2

Scoring

The total score ranges from 0 to 21, calculated by summing the scores of all seven items. 1, 2

Interpretation

GAD-7 scores are interpreted as follows: 1, 2

Score Range	Severity Level	Clinical Significance
0-4	Minimal/None	No or minimal anxiety symptoms [1]
5-9	Mild	Mild anxiety symptoms [1]
10-14	Moderate	Moderate anxiety symptoms [1]
15-21	Severe	Severe anxiety symptoms [1]

• The GAD-7 has excellent reliability (Cronbach's alpha = 0.92) and test-retest reliability of 0.83 1
• At the recommended cut-off of ≥10, the GAD-7 demonstrates sensitivity of 0.64 and specificity of 0.91 for detecting generalized anxiety disorder 3
• The GAD-7 is sensitive to change over treatment and can be used to monitor symptom progression 4, 5

Treatment Recommendations by Score Category

Minimal Anxiety (0-4): Care Pathway 1

Patients with scores of 0-4 require monitoring only, with no active intervention needed. 1, 6

• Continue routine screening at regular intervals 1
• Reassess at diagnosis/start of treatment, during treatment, at 3,6, and 12 months post-treatment, at recurrence/progression, and during times of personal transition 1

Mild Anxiety (5-9): Care Pathway 1

Patients with scores of 5-9 should receive low-intensity interventions. 1, 6

• Offer referral to educational and support services 1
• Provide psychoeducation about anxiety and coping strategies 1
• Assess for effective coping skills and access to social support 1
• Consider possible comorbid anxiety disorders such as panic disorder or social phobia 1
• Monitor with follow-up reassessment 6

Moderate Anxiety (10-14): Care Pathway 2

Patients with scores of 10-14 require referral to psychology and/or psychiatry for formal diagnosis and treatment. 1, 6

Before initiating treatment, immediately screen for:

• Risk of harm to self or others, which requires emergency psychiatric evaluation 1, 6
• Severe agitation, psychotic symptoms, or confusion/delirium, which warrant urgent specialist evaluation 1, 6

Assess for comorbidities and risk factors:

• Screen for major depressive disorder using PHQ-9 or direct questioning about depressed mood and anhedonia 6
• Evaluate for alcohol or substance use/abuse, which requires concurrent treatment 1, 6
• Assess for other chronic medical illnesses, prior anxiety disorder history, and family history of anxiety or mood disorders 1, 6

Determine functional impairment:

• Ask specific questions about how anxiety interferes with work, home responsibilities, and relationships 6
• Moderate GAD typically causes mild to moderate functional impairment 6

High-intensity intervention options include: 1

• Cognitive behavioral therapy (CBT) 1
• Behavioral activation 1
• Structured physical activity/exercise 1
• Acceptance and commitment therapy 1
• Psychosocial interventions with empirically supported components (relaxation, problem solving) 1
• Group treatment led by licensed mental health professionals addressing stress reduction, positive coping, and enhancing social support 1

If specialist access is limited:

• Initiate education about GAD and guided self-help 6
• Consider starting an SSRI or SNRI 6
• Arrange active monitoring with follow-up in 2-4 weeks to reassess symptoms and functional impairment 6

Severe Anxiety (15-21): Care Pathway 3

Patients with scores of 15-21 require immediate referral to a licensed mental health professional for diagnosis and intensive treatment. 1, 6

Immediate safety assessment is mandatory:

• Screen for suicidal ideation, self-harm thoughts, or intent to harm others; any positive response requires immediate psychiatric referral or emergency evaluation 1, 6
• Facilitate a safe environment and initiate one-to-one observation if risk is present 1

Symptoms at this level:

• Interfere moderately to markedly with daily functioning 1
• May include fatigue, sleep disturbances, irritability, and concentration difficulties 1
• Require assessment for comorbid anxiety diagnoses such as panic disorder or social phobia 1
• Necessitate evaluation for comorbid mood disorders including major depressive disorder 1

Treatment approach:

• Individual psychological therapy delivered by a licensed mental health professional 1
• Consider combined psychotherapy and pharmacotherapy for moderate to severe symptoms 6
• If symptoms do not remit or worsen with initial treatment, consider psychosocial group interventions 1

Critical Considerations Across All Severity Levels

Common pitfalls to avoid:

• Missing comorbid depression—always screen with PHQ-9 or direct questioning, as GAD and major depression frequently co-occur 6
• Overlooking substance use disorders, which require concurrent treatment and complicate anxiety management 6
• Failing to assess functional impairment, which guides treatment intensity 6
• Not screening for medical conditions that mimic anxiety (hyperthyroidism, cardiac arrhythmias, hyperparathyroidism) 6

Reassessment strategy:

• After 8 weeks of treatment, if symptom reduction and satisfaction are poor despite good compliance, alter the treatment course by adding or changing interventions 1
• Use the GAD-7 for ongoing monitoring, as it is sensitive to change and can track treatment response 4, 5